ArticleHead & neck2026
Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma.Cancer immunology, immunotherapy : CII · 2026Trial
- Pathological Pathways of Olfactory Neuroblastoma: From Molecular Mechanisms to Targeted Therapy: A Narrative Review.Cancers · 2026Review
- Epigenetic alterations in head and neck cancer: a brief update.Virchows Archiv : an international journal of pathology · 2026Review
- Review
- Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma.Head & neck · 2026Article
- Systemic Therapy for High-Grade Olfactory Neuroblastoma: From Molecular Lineages to Targeted and Immune Strategies.Cancer management and research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeOlfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T-cell-mediated killing and susceptibility to immune checkpoint inhibitors in a variety of cancers. We aimed to evaluate the expression and activity of EZH2 in ONB and its association with immune characteristics. MATERIALS AND
methodsWe studied a cohort of 36 ONB real-world patient samples that underwent molecular profiling at a centralized lab (Caris Life Science). To infer EZH2 methyltransferase activity, we adopted an EZH2 gene repression signature (ERS) score: ONB samples were stratified into ERS-low and ERS-high subgroups, corresponding to high and low inferred EZH2 methyltransferase activity, respectively. Transcriptomic data were utilized to calculate the T-cell-inflamed (TCI) score and mitogen-activated protein kinase (MAPK) pathway activation score (MPAS). Tumor immune microenvironment composition was inferred from tumor-derived bulk RNA sequencing data. We analyzed immunologic differences between ERS-low and ERS-high ONB.
resultsIn ERS-high ONB, we observed a higher expression of immune-related genes, a higher proportion of TCI tumors, and an enrichment in inflammatory pathways. ERS-high ONB also displayed increased macrophages, and to a lesser extent, B cells and CD8
conclusionsTaken together, our data suggest that low EZH2 activity is associated with a more immunogenic microenvironment, paving the way for potential combinations of EZH2 inhibitors with checkpoint blockade in ONB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.